Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
Media formats available:
Details
Documents
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NYDr. Mascarenhas has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research Support: AbbVie, BMS, CTI/SOBI, Geron, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia
Consulting Fees: AbbVie, BMS, CTI/SOBI, Galecto, Geron, Incyte, Kartos, Karyopharm, Merck, MorphoSys, Novartis, Pfizer, PharmaEssentia, Roche, SumitomoGabriela Hobbs, MD
Clinical Director, Leukemia Service
Assistant in Medicine
Massachusetts General Hospital
Boston, MADr. Hobbs has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research Support: ASH-AMFDP
Consulting Fees: AbbVie, BMS, Cogent, GSK, MorphoSys, Novartis, Pfizer, PharmaEssentia,
Spouse: Employeed at Regeneron GeneticsReviewers/Content Planners/Authors:
- Robert Garris has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Apply patient- and disease-related features, current guidelines, and recent clinical evidence to personalize the treatment of myelofibrosis (MF), including management of treatment-related toxicities
- Identify patterns of suboptimal first-line treatment response in patients with MF, including treatment resistance and treatment intolerance
- Apply the latest clinical evidence and best practices to tailor treatment selection and management for patients with MF experiencing associated thrombocytopenia and/or anemia
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists and oncologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with myelofibrosis.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 7/19/2025 PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.1 The Universal Activity Number for this program is JA0006235-0000-24-079-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.Commercial Support
This activity is supported by an independent educational grant from Sobi, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment.pdf
How and When to Manage Ruxolitinib Failure.pdf
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis.pdf
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum.pdf
Managing Myelofibrosis-Associated Anemia.pdf
Improving Transfusion Independence With JAK Inhibitor Therapy.pdf
Managing Myelofibrosis-Associated Thrombocytopenia.pdf
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis.pdf
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 ×109/L?.pdf
Real-World Experience With Pacritinib in the US.pdf
